
Impact of obesity on immune function and depressive disorder: integrative review

*Impacto da obesidade na função imune e no transtorno depressivo:
revisão integrativa*

*Impacto de la obesidad en la función inmunitaria
y el trastorno depresivo: revisión integradora*

Tainá Patrícia Teixeira Bezerra



[ORCID](#) - [Lattes](#)

Roberto Mendes dos Santos - [ORCID](#) - [Lattes](#)

Alfredo José Minervino - [ORCID](#) - [Lattes](#)

Naiara Naiana Dejani - [ORCID](#) - [Lattes](#)

ABSTRACT

Objective: This integrative review aims to search and analyze scientific evidence on the relationship between obesity, immune function, and depressive disorder. **Methods:** The present study is a descriptive review of literature concerning the keywords: obesity, depression, immunologic, inflammation, psychoneuroimmunology and cytokines. The inclusion criteria were: articles published in english; articles referring to the integrative review and articles published and indexed in the [PubMed](#) database in the last 17 years. **Results:** A large amount of evidence indicates that immune function seems to be compromised in obesity and has, through this, a relationship in the trigger of depressive symptom. However, more evidence is still needed to better elucidate the pathophysiology components of depressive incidences through obesity and associated immunological alterations. **Conclusions:** The pathophysiological scenario of obesity is closely related to changes in immune function, and these may promote depressive symptoms through various physiological mechanisms and thus negatively impact mental health status.

Keywords: depressive disorder, immune system, obesity, inflammation, cytokines

RESUMO

Objetivo: Esta revisão integrativa tem como objetivo pesquisar e analisar evidências científicas sobre a relação entre a obesidade, a função imune e o transtorno depressivo. **Métodos:** O presente estudo é uma revisão descritiva da literatura referente às palavras-chave: obesidade, depressão, imunológico, inflamação, psiconeuroimunologia e citocinas. Os critérios de inclusão foram: artigos publicados em inglês, artigos referentes à revisão integrativa e artigos publicados e indexados no banco de dados [PubMed](#) nos últimos 17 anos. **Resultados:** Uma grande quantidade de evidências indica que a função imunológica parece estar comprometida na obesidade e possui, através desta, relação com desencadeamentos de sintomas depressivos. Entretanto, ainda são necessárias mais evidências para melhor elucidação dos componentes fisiológicos de etiologia das incidências depressivas através da obesidade e das alterações imunológicas associadas. **Conclusões:** O cenário fisiopatológico da obesidade está intimamente relacionado a alterações na função imunológica e estas podem promover desencadeamentos de sintomatologias depressivas através de mecanismos fisiológicos diversos e desta forma impactar negativamente o estado de saúde mental.

Palavras-chave: desordem depressiva, sistema imunológico, obesidade, inflamação, citocinas

RESUMEN

Objetivo: Esta revisión integradora tiene como objetivo buscar y analizar la evidencia científica sobre la relación entre obesidad, función inmune y trastorno depresivo. **Métodos:** El presente estudio es una revisión descriptiva de la literatura relativa a las palabras clave: obesidad, depresión, inmunológico, inflamación, psiconeuroinmunología y citocinas. Los criterios de inclusión fueron: artículos publicados en inglés, artículos referentes a la revisión integrativa y artículos publicados e indexados en la base de datos [PubMed](#) en los últimos 17 años. **Resultados:** Una gran cantidad de pruebas indica que la función inmunitaria parece estar comprometida en la obesidad y está relacionada con los síntomas depresivos. Sin embargo, aún se necesitan más pruebas para dilucidar mejor los componentes fisiológicos de la etiología de las incidencias depresivas a través de la obesidad y las alteraciones inmunológicas asociadas. **Conclusiones:** El escenario fisiopatológico de la obesidad está



estrechamente relacionado con los cambios en la función inmunitaria y éstos pueden promover el desencadenamiento de síntomas depresivos a través de diversos mecanismos fisiológicos y, por tanto, repercutir negativamente en el estado de salud mental.

Palabras clave: trastorno depresivo, sistema inmune, obesidade, inflamación, citoquinas

Como citar: Bezerra TPT, Santos RM, Minervino AJ, Dejana NN. Impact of obesity on immune function and depressive disorder: integrative review. *Debates em Psiquiatria*, Rio de Janeiro. 2023;13:1-18. <https://doi.org/10.25118/2763-9037.2023.v13.631>

Conflito de interesses: declaram não haver

Fonte de financiamento: declaram não haver

Parecer CEP: Não se aplica

Recebido em: 21/03/2023

Aprovado em: 14/06/2023

Publicado em: 22/06/2023

Introduction

Depressive disorder is a multifactorial disease of high pathophysiological complexity [1]. In 2019, the Global Burden of Disease, Injury, and Risk Factors (GBD) study ranked depression among the twenty-five diseases with the highest burden and disability worldwide [2]. The prevalence of global obesity has grown in recent decades and has established itself as a significant public health problem worldwide [3]. Despite the impact of depression and obesity in the global health context, the mechanisms of etiology of both diseases remain not fully understood.

The prevalence of mental diseases has substantially increased. It has grown in correlation with changes in the dietary profile of the human diet with increased consumption of ultra-processed and energy-dense foods [4] and consequent weight gain. Obesity and other chronic diseases are associated with alterations in immune response, leukocyte counts and cellular immune response components [5], and various physiological changes.

Studies estimate that obese individuals have around a 55% of chance of developing depressive symptoms throughout life [6]. In this sense, studies have shown that obesity and its metabolic and immunological alterations positively correlate with incidences of depression [7]. In addition, growing evidence has demonstrated that abdominal adiposity and a food consumption profile predominantly based on proinflammatory and high-energy foods, common in the population affected by obesity, may influence the onset of depressive disorder [8 - 10].

Bidirectional associations between obesity and depression have been reported, demonstrating that individuals affected by depressive disorder become more susceptible to weight gain induced by reduced-quality food choices [6]. However, the holistic understanding of immune mechanisms associated with gut-brain communication in the triggering of depressive disorders remains to be fully elucidated.

Dysregulation in immune response has been associated with depressive symptoms through multifactorial inflammatory mechanisms and interaction with the central nervous system (CNS) via the hypothalamic-pituitary-adrenal axis [7]. Dietary and obesity patterns have been strongly linked to alterations in the profile of cytokine secretion, including elevated production of interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF- α), and C-reactive protein (CRP), triggering neuroinflammatory processes and metabolic disorders that may result in depressive incidences [11].

Therefore, there is increasing evidence reporting the influence and impact of obesity on immune response and the incidence of psychic alterations. However, there is still a need for further studies to elucidate this intercommunicating scenario. In this context, this review aims to establish a survey of evidence and a better understanding of the impact of obesity on immune function and in triggering depressive disorders.

Methods

The present study is a descriptive review of literature based on [PubMed](#) database. The scientific publications on obesity and depressive disorders, with highlights to immune mediators involved in both diseases, were selected based on the keywords: Obesity, Depression, Immunologic, Inflammation, Psychoneuroimmunology, and Cytokines. The inclusion criteria defined for the selection of articles were: articles published in English; articles referring to the integrative review and articles published and indexed in the referred database in the last 17 years.

Results

Obesity and the immune system

Obesity is characterized by chronic low-grade inflammation related to local origins in adipose tissue and subsequent systemic inflammatory state [5]. Positive associations between obesity and changes in inflammatory cytokines such as TNF- α , IL-6, and C-reactive protein (CRP) have been reported [12 - 14] [Figure 1]. Indeed, an increase in serum concentrations of complement components, including C3 and C4, and CRP has been observed in obese adolescents aged 13-17 years [14], and elevated serum levels of IL-6 and TNF- α have been described in obese Korean adults [12]. Abdominal fat accumulation, assessed by waist circumference measurement, is positively correlated with proinflammatory markers such as complement C3, CRP, IL-6, and retinol-binding protein (RBP) [13]. These findings indicate a possible link between the profile of body fat distribution and immune function alterations.

The communicative links between nutritional status and immune competence have been supported in the literature through the reported association of malnutrition with impaired immune function. Malnutrition leads to increased vulnerability to infections in underweight populations. However, understanding obesity as a disorder of nutritional status has also been associated with diverse immunological impairments, including association with increased ectopic lipogenesis in primary lymphoid organs, distinct innate and adaptive cell populations in adipose tissue, and increased serum levels of inflammatory mediators [15].

The adipose tissue of obese individuals has a more significant accumulation of macrophages, T cells, B cells, and mast cells than the adipose tissue of lean individuals [16, 17]. Indeed, innate and adaptive cells in the obese adipose tissue show a proinflammatory profile, which favors the maintenance of inflammation [16].

Obese adipose tissue has an increased population of resident macrophages, which comprise up to 40% of total tissue cells [15, 18]. The profile of macrophages in obese adipose tissue is characterized by a predominance of the M1 subtype, which produces proinflammatory cytokines favoring inflammation, in contrast to the M2 subtype, predominantly found in lean adipose tissue, which is associated with an anti-inflammatory response [15]. Inflammatory pathways are sustained in obesity and promote the elevated secretion of proinflammatory cytokines, such as TNF- α and IL-1 β , which may have local and systemic effects,

promoting metabolic dysregulation associated with insulin resistance [18]. However, differences are found in a distinct type of adipose tissue, subcutaneous and visceral. Macrophages produce more proinflammatory cytokines in visceral adipose tissue than in subcutaneous tissue [19]. Indeed, more detrimental metabolic and systemic effects are observed when body fat distribution is predominantly visceral rather than subcutaneous.

Yang et al. [16] observed that subcutaneous adipose tissue harbors significantly higher numbers of CD4 and CD8 T cells, with excessive secretions of proinflammatory cytokines in obese women (BMI>40, n=6) compared to lean women (BMI<24, n=6). Moreover, reduced T cell receptor (TCR) diversity was also identified in lymphocytes from subcutaneous and visceral adipose tissue of obese mice compared to lean mice, demonstrating a possible reduction in thymopoiesis and compromised immune surveillance associated with overweight [16].

Differences in CD4 T cell (Th) subpopulations, including Th1, Th2, and regulatory T cells (Treg), are found in obese individuals. The predominance of the Th1 population, impaired Treg number and activity are observed in obese individuals [18] [Figure 2]. Furthermore, the reduction of Treg in obesity has been associated with impaired immunoregulation, increased proinflammatory mediators, and the development of metabolic diseases in experimental studies [20].

Neuroinflammation and depression in obesity

Neuroinflammatory factors have been associated with significant impacts on the interaction between neurobiological trigger mechanisms of major depressive disorder, including reductions in serotonin concentration and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis [21].

Clinical studies have demonstrated an association between serotonin metabolism in depressive patients, depletions in tryptophan amino acid (TRP) concentration, and incidences of depressive symptoms [22]. Serotonin (5HT) is synthesized through a metabolic route characterized by the action of the tryptophan hydroxylase enzyme on the tryptophan amino acid (TRP); however, changes in tryptophan catabolism through metabolic ways alternative to serotonin synthesis and precursors of metabolic products that generate oxidative stress have been strongly associated to proinflammatory cytokines and neuroinflammation [21, 23, 24].

Presumably, TRP conversion into its metabolite product, kynurenine (KYN), reduces serotonin availability in the CNS, which is essential in regulating mood states [25 - 27].

Considering that obesity is characterized by a state of low-grade inflammation, the impact of its inflammatory manifestations has been increasingly investigated as a link to incidences of mood disorders and psychiatric pathologies. Experimental and clinical models have demonstrated a correlation between mood disorders with diseases in which pathophysiology evokes inflammatory mechanisms [27, 28]. The depressive etiology is linked to the expression of inflammatory cytokines with influence on the HPA axis, promoting changes in glucocorticoid secretions and endocrine negative feedback loops [23, 29].

Hyperactivity of the HPA axis determined by elevations in cortisol levels is the breakthrough for the neurobiology adjacent to psychiatric disorders, as it has been shown that prolonged exposure to high levels of circulating cortisol may promote damage in limbic brain regions, including the amygdala and hippocampus, which are responsible for regulating mood states [30]. Interestingly, hyperactivation of the HPA axis and increased cortisol levels have been found in obese individuals with mental disorders [31].

The bidirectional intercommunication between obesity and depression has multifactorial origins [Figure 3]. Among them, homeostatic dysregulation in the HPA axis and immune-inflammatory activations are among the communicating factors for the etiological understanding of alterations in mood states [32] reflected in obese individuals.

Considering that inflammatory mediators strongly modulate the HPA axis, Milaneschi et al. suggest that chronic inflammation typical of obesity may provide perturbations in glucocorticoid and cortisol binding receptors, thus triggering persistent elevations in plasma glucocorticoid concentrations in obese individuals [32] and may provide depressive symptoms through the glucocorticoid-sensitive mesolimbic neurofunctional.

As reported by Troubat et al. and supported by previous studies, abnormalities of the HPA axis are observed in depressive illness and corroborate with studies demonstrating higher salivary and urinary glucocorticoid concentrations in patients diagnosed with the depressive disorder [21].

Milaneschi et al. reported that patients diagnosed with atypical subtype of depression, marked by hypoactivity, mood reactivity, hyperphagia, hypersomnia, and extreme severe paralysis [33], had a higher predisposition to overweight and obesity (BMI \geq 24.9) and high levels of CRP [34]. Indeed, this subtype of depression has been associated with inflammatory factors, such as increased IL-2 and reduced IL-4 serum levels [35].

The relationship between obesity and depression has also been more recently supported through the strong association between waist-to-hip ratio in individuals with increased abdominal adiposity and depressive incidences, with a prevalence of ratios on the order of 1.38 (95% CI, 1.22-1.57) [36].

High levels of CRP in depressed individuals were reported in a cohort study between 1999-2004 [37]. Indeed, increased levels of CRP are found in approximately 25% of individuals diagnosed with major depression, and elevations in circulating levels of IL-6 are also reported, highlighting that patients with chronic inflammatory-based pathologies may present increased rates of attempted suicidal ideation [38]. In this way, clinical interventions with anti-inflammatory drugs may become strategies to prevent severe cases of depression [38].

The primary immunological characterization of obesity concerns the profile of chronic low-grade inflammation and its associations with cellular and humoral immune responses. Among the alterations of immune activity, activation of the inflammasome, a sensor of the innate immune system, has been attributed as one of the mechanisms involved in depression [39].

The inflammasome protein complex, formed in the cytoplasm in response to pathogens recognition or cellular damage, recruits caspase-1, a protease responsible for cleaving the immature form of pro-IL-1 β and pro-IL-18, into mature forms of IL-1 β and IL-18 cytokines. Interestingly, an experimental study with mice reported that caspase-1 inhibition has a protective effect on anxious and depressive behaviors [40]. Indeed, the secretion of IFN- γ by resident adipose tissue T cells has been associated with increased expression of the caspase-1 and NLRP3 inflammasome in adipocytes from obese individuals, favoring proinflammatory pathways that sustain the chronic inflammation typical of obesity [32, 39, 41] and may thus comprise an etiological way of incidence for depressive pathology.

Conclusion and future perspectives

Dysregulation in neuroendocrine pathways and neurotransmitter production with direct physiological importance for mood state maintenance are strongly correlated with proinflammatory cytokines and patterns of immune cell activation, which are also found in obesity. The connection of inflammation, obesity and depressive disorders has been identified in observational studies assessing the high incidence of depression in obese individuals, while inflammation in obesity explains in part the depressive symptomatology. However, despite advances in understanding the integrative pathophysiology between obesity and depression onset through immune dysfunctions, more evidence is still needed to evaluate and elucidate ideal clinical and pharmacological management for the prevention and treatment of depressive conditions in obese individuals.

Referências

1. Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. *Depress Anxiety*. 2014;31(6):459-71. <https://doi.org/10.1002/da.22217> - PMID:24272961
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1789-858. [https://doi.org/10.1016/S0140-6736\(18\)32279-7](https://doi.org/10.1016/S0140-6736(18)32279-7) - PMID:30496104
3. Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, Mozaffarian D, Swinburn B, Ezzati M. The obesity transition: stages of the global epidemic. *Lancet Diabetes Endocrinol*. 2019;7(3):231-40. [https://doi.org/10.1016/S2213-8587\(19\)30026-9](https://doi.org/10.1016/S2213-8587(19)30026-9) - PMID:30704950
4. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, O'Keefe JH, Brand-Miller J. Origins and evolution of the western diet: health implications for the 21st century. *Am J Clin Nutr*. 2005;81(2):341-54. <https://doi.org/10.1093/ajcn.81.2.341> PMID:15699220

5. Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. *Proc Nutr Soc.* 2012;71(2):332-8. <https://doi.org/10.1017/S0029665112000092> - PMID:22429824
6. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiatry.* 2010;67(3):220-9. <https://doi.org/10.1001/archgenpsychiatry.2010.2> PMID:20194822
7. Jantaratnotai N, Mosikanon K, Lee Y, McIntyre RS. The interface of depression and obesity. *Obes Res Clin Pract.* 2017;11(1):1-10. <https://doi.org/10.1016/j.orcp.2016.07.003> - PMID:27498907
8. Shivappa N, Hébert JR, Veronese N, Caruso MG, Notarnicola M, Maggi S, Stubbs B, Firth J, Fornaro M, Solmi M. The relationship between the dietary inflammatory index (DII®) and incident depressive symptoms: a longitudinal cohort study. *J Affect Disord.* 2018;235:39-44. <https://doi.org/10.1016/j.jad.2018.04.014> PMID:29649709
9. Firth J, Marx W, Dash S, Carney R, Teasdale SB, Solmi M, Stubbs B, Schuch FB, Carvalho AF, Jacka F, Sarris J. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. *Psychosom Med.* 2019;81(3):265-80. <https://doi.org/10.1097/PSY.0000000000000673> - PMID:30720698
PMCID:PMC6455094
10. Hamer M, Batty GD, Kivimaki M. Risk of future depression in people who are obese but metabolically healthy: the english longitudinal study of ageing. *Mol Psychiatry.* 2012;17:940-5. <https://doi.org/10.1038/mp.2012.30> - PMID:22525487
PMCID:PMC3428506
11. Hryhorczuk C, Sharma S, Fulton SE. Metabolic disturbances connecting obesity and depression. *Front Neurosci.* 2013;7:177. <https://doi.org/10.3389/fnins.2013.00177> - PMID:24109426
PMCID:PMC3791387
12. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6.

Diabetes Res Clin Pract. 2005;69(1):29-35.

<https://doi.org/10.1016/j.diabres.2004.11.007> - PMID:15955385

13. Hermsdorff HHM, Zulet MA, Puchau B, Martínez JA. Central adiposity rather than total adiposity measurements are specifically involved in the inflammatory status from healthy young adults. *Inflammation*. 2011;34(3):161-70. <https://doi.org/10.1007/s10753-010-9219-y> - PMID:20467889
14. Martinez-Gomez D, Eisenmann JC, Warnberg J, Gomez-Martinez S, Veses A, Veiga OL, Marcos A; AFINOS Study Group. Associations of physical activity, cardiorespiratory fitness and fatness with low-grade inflammation in adolescents: the AFINOS Study. *Int J Obes (Lond)*. 2010;34:1501-7. <https://doi.org/10.1038/ijo.2010.114> PMID:20531354
15. Kanneganti TD, Dixit VD. Immunological complications of obesity. *Nat Immunol*. 2012;13(8):707-12. <https://doi.org/10.1038/ni.2343> - PMID:22814340
16. Yang H, Youm YH, Vandanmagsar B, Ravussin A, Gimble JM, Greenway F, Stephens JM, Mynatt RL, Dixit VD. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. *J Immunol*. 2010;185(3):1836-45. <https://doi.org/10.4049/jimmunol.1000021> PMID:20581149 - PMCID:PMC4829921
17. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. *Nat Med*. 2011;17(5):610-7. <https://doi.org/10.1038/nm.2353> PMID:21499269 - PMCID:PMC3270885
18. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. *Nat Med*. 2012;18(3):363-74. <https://doi.org/10.1038/nm.2627> PMID:22395709

19. O'Rourke RW, Metcalf MD, White AE, Madala A, Winters BR, Maizlin II, Jobe BA, Roberts CT Jr, Slifka MK, Marks DL. Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. *Int J Obes (Lond)*. 2009;33:978-90. <https://doi.org/10.1038/ijo.2009.133> PMID:19564875 - PMCID:PMC3150185
20. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. *Nat Med*. 2009;15(8):930-9. <https://doi.org/10.1038/nm.2002> - PMID:19633656 PMCID:PMC3115752
21. Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, Brizard B, Hage WE, Surget A, Belzung C, Camus V. Neuroinflammation and depression : a review. *Eur J Neurosci*. 2021;53(1):151-71. <https://doi.org/10.1111/ejn.14720> PMID:32150310
22. Moreno FA, Parkinson D, Palmer C, Castro WL, Misiaszek J, El Khoury A, Mathé AA, Wright R, Delgado PL. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. *Eur Neuropsychopharmacol*. 2010;20(1):18-24. <https://doi.org/10.1016/j.euroneuro.2009.10.003> PMID:19896342 - PMCID:PMC2794896
23. O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW, Dantzer R. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus calmette-guerin. *J Neurosci*. 2009;29(13):4200-9. <https://doi.org/10.1523/JNEUROSCI.5032-08.2009> PMID:19339614 - PMCID:PMC2835569
24. Badawy AAB. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. *Int J Tryptophan Res*. 2017;10:1-20. <https://doi.org/10.1177/1178646917691938> - PMID:28469468 PMCID:PMC5398323
25. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. *Pharmacol Ther*.

2011;130(2):226-38.

<https://doi.org/10.1016/j.pharmthera.2011.01.014> PMID:21334376
PMCID:PMC3072299


26. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci*. 2008;9:46-56. <https://doi.org/10.1038/nrn2297> - PMID:18073775
PMCID:PMC2919277
27. O'Connor JC, Lawson MA, André C, Briley EM, Szegedi SS, Lestage J, Castanon N, Herkenham M, Dantzer R, Kelley KW. Induction ofIDO by bacille calmette-guérin is responsible for development of murine depressive-like behavior. *J Immunol*. 2009;182(5):3202-12. <https://doi.org/10.4049/jimmunol.0802722> PMID:19234218 - PMCID:PMC2664258
28. Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, Mortensen PB. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. *JAMA Psychiatry*. 2013;70(8):812-20. <https://doi.org/10.1001/jamapsychiatry.2013.1111> PMID:23760347
29. Benatti C, Blom JMC, Rigillo G, Alboni S, Zizzi F, Torta R, Brunello N, Tascedda F. Disease-induced neuroinflammation and depression. *CNS Neurol Disord Drug Targets*. 2016;15(4):414-33. <https://doi.org/10.2174/1871527315666160321104749> PMID:26996176
30. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. *Physiol Rev*. 2007;87(3):873-904. <https://doi.org/10.1152/physrev.00041.2006> PMID:17615391
31. Wester VL, Staufenbiel SM, Veldhorst MAB, Visser JA, Manenschijn L, Koper JW, Klessens-Godfroy FJM, van den Akker ELT, van Rossum EFC. Long-term cortisol levels measured in scalp hair of obese patients. *Obesity (Silver Spring)*. 2014;22(9):1956-8. <https://doi.org/10.1002/oby.20795> - PMID:24852462
32. Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity : evidence of shared biological mechanisms.

Mol Psychiatry. 2019;24:18-33. <https://doi.org/10.1038/s41380-018-0017-5> - PMID:29453413


- 33. Juruena MF, Cleare AJ. Superposição entre depressão atípica, doença afetiva sazonal e síndrome da fadiga crônica. Rev Bras Psiquiatr. 2007;29 Suppl 1:S19-26. <https://doi.org/10.1590/S1516-44462007000500005> - PMID:17546343
- 34. Milaneschi Y, Lamers F, Peyrot WJ, Baune BT, Breen G, Dehghan A, Forstner AJ, Grabe HJ, Homuth G, Kan C, Lewis C, Mullins N, Nauck M, Pistis G, Preisig M, Rivera M, Rietschel M, Streit F, Strohmaier J, Teumer A, Van der Auwera S, Wray NR, Boomsma DI, Penninx BWJH; CHARGE Inflammation Working Group and the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Genetic association of major depression with atypical features and obesity-related immunometabolic dysregulations. JAMA Psychiatry. 2017;74(12):1214-25. <https://doi.org/10.1001/jamapsychiatry.2017.3016> PMID:29049554 - PMCID:PMC6396812
- 35. Yoon HK, Kim YK, Lee HJ, Kwon DY, Kim L. Role of cytokines in atypical depression. Nord J Psychiatry. 2012;66(3):183-8. <https://doi.org/10.3109/08039488.2011.611894> - PMID:21936732
- 36. Xu Q, Anderson D, Lurie-Beck J. The relationship between abdominal obesity and depression in the general population: a systematic review and meta-analysis. Obes Res Clin Pract. 2011;5(4):e267-78. <https://doi.org/10.1016/j.orcp.2011.04.007> PMID:24331129
- 37. Hickman RJ, Khambaty T, Stewart JC. C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination survey (NHANES) 1999-2004. J Behav Med. 2014;37:621-9. <https://doi.org/10.1007/s10865-013-9510-0> - PMID:23624671
- 38. Kappelmann N, Arloth J, Georgakis MK, Czamara D, Rost N, Ligthart S, Khandaker GM, Binder EB. Dissecting the association between inflammation, metabolic dysregulation, and specific depressive symptoms: a genetic correlation and 2-sample mendelian randomization study. JAMA Psychiatry. 2021;78(2):161-70.

<https://doi.org/10.1001/jamapsychiatry.2020.3436> PMID:33079133
PMCID:PMC7577200


39. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. *Brain Behav Immun*. 2013;31:105-14.
<https://doi.org/10.1016/j.bbi.2012.12.008> - PMID:23261775
PMCID:PMC4426992
40. Wong ML, Inserra A, Lewis MD, Mastronardi CA, Leong L, Choo J, Kentish S, Xie P, Morrison M, Wesselingh SL, Rogers GB, Licinio J. Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. *Mol Psychiatry*. 2016;21:797-805. <https://doi.org/10.1038/mp.2016.46>
PMID:27090302 - PMCID:PMC4879188
41. Yin Z, Deng T, Peterson LE, Yu R, Lin J, Hamilton DJ, Reardon PR, Sherman V, Winnier GE, Zhan M, Lyon CJ, Wong STC, Hsueh WA. Transcriptome analysis of human adipocytes implicates the NOD-like receptor pathway in obesity-induced adipose inflammation. *Mol Cell Endocrinol*. 2014;394(1-2):80-7.
<https://doi.org/10.1016/j.mce.2014.06.018> - PMID:25011057
PMCID:PMC4219530



↑ **Figure 1.** Inflammatory mediators associated with obesity. Obesity is related to increased secretion of inflammatory cytokines, including TNF- α , IL-6 and CRP (C - reactive protein)
Created with <https://www.biorender.com/>
[Licença de uso de imagem](#)



🏠 **Figure 2.** CD4 T cell population associated with obesity. Predominance of Th1 and reduction of Treg cell population are characteristic of inflammation in obese individuals. Created with <https://www.biorender.com/>
[Licença de uso de imagem](#)



➤ **Figure 3.** Multifactorial aspects associated with obesity and mood alterations. Social, genetic, dietary, and individual habits are associated with mood changes and the onset of depressive symptoms.

Created with <https://www.biorender.com/>
[Licença de uso de imagem](https://www.biorender.com/)